Everest Refocuses After Trodelvy Twist
A shift in investor sentiment in 2021 hit Everest hard when it was expanding the commercial team for cancer drug Trodelvy. Entering 2022, the sustained downturn in the capital market environment eventually changed the way the Chinese biotech considers launching drugs in the market.
You may also be interested in...
Biogen’s return of rights to the BTK inhibitor orelabrutinib to originator InnoCare signals an ongoing tough reality for Chinese biotechs with go-global ambitions.
China’s top securities regulator is slowing down the review of initial public offering applications across the board to “stabilize” the stock market. But event prior to the move, Chinese biotechs were operating already under a continuously tightening IPO environment.
Plus deals involving Kelun Biotech, Pierre Fabre/Vertical, Novo Nordisk/Broad Institute, ABL Bio/Synaffix, Kriya/Tramontane, Palisade/Giiant and more.